Abstract
Background The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major in the cardiac sub-study of the EPIC trial. Design and Methods Eligible patients with myocardial T2* greater than 5 to less than 20 ms received deferasirox, with the primary endpoint being the change in T2* from baseline to two years. Results Baseline myocardial T2* was severe (>5 to
Original language | English |
---|---|
Pages (from-to) | 48-54 |
Number of pages | 7 |
Journal | Haematologica |
Volume | 96 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2011 |
Keywords
- β-thalassemia major
- Cardiac iron overload
- Deferasirox
- Iron chelation
- Myocardial T2*
ASJC Scopus subject areas
- Hematology